These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37428016)

  • 1. Rates of Intervention and Cancer Detection on Initial versus Subsequent Whole-body MRI Screening in Li-Fraumeni Syndrome.
    Kagami LAT; Du YK; Fernandes CJ; Le AN; Good M; Duvall MM; Baldino SE; Powers J; Zelley K; States LJ; Mathew MC; Katona BW; MacFarland SP; Maxwell KN
    Cancer Prev Res (Phila); 2023 Sep; 16(9):507-512. PubMed ID: 37428016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic.
    Bojadzieva J; Amini B; Day SF; Jackson TL; Thomas PS; Willis BJ; Throckmorton WR; Daw NC; Bevers TB; Strong LC
    Fam Cancer; 2018 Apr; 17(2):287-294. PubMed ID: 28988289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-body magnetic resonance imaging of Li-Fraumeni syndrome patients: observations from a two rounds screening of Brazilian patients.
    Paixão D; Guimarães MD; de Andrade KC; Nóbrega AF; Chojniak R; Achatz MI
    Cancer Imaging; 2018 Aug; 18(1):27. PubMed ID: 30107858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening with whole-body magnetic resonance imaging in pediatric subjects with Li-Fraumeni syndrome: A single institution pilot study.
    O'Neill AF; Voss SD; Jagannathan JP; Kamihara J; Nibecker C; Itriago-Araujo E; Masciari S; Parker E; Barreto M; London WB; Garber JE; Diller L
    Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 29077256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol.
    Dixon-Zegeye M; Shaw R; Collins L; Perez-Smith K; Ooms A; Qiao M; Pantziarka P; Izatt L; Tischkowitz M; Harrison RE; George A; Woodward ER; Lord S; Hawkes L; Evans DG; Franklin J; Hanson H; Blagden SP
    Trials; 2024 Feb; 25(1):103. PubMed ID: 38308321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Whole-body MRI in cancer predisposition syndromes].
    Herrmann J; Esser M; Brecht I; Tsiflikas I; Schäfer JF
    Radiologie (Heidelb); 2022 Dec; 62(12):1017-1025. PubMed ID: 36098807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Li-Fraumeni Syndrome and Whole-Body MRI Screening: Screening Guidelines, Imaging Features, and Impact on Patient Management.
    Consul N; Amini B; Ibarra-Rovira JJ; Blair KJ; Moseley TW; Taher A; Shah KB; Elsayes KM
    AJR Am J Roentgenol; 2021 Jan; 216(1):252-263. PubMed ID: 33151095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic
    Bancroft EK; Saya S; Brown E; Thomas S; Taylor N; Rothwell J; Pope J; Chamberlain A; Page E; Benafif S; Hanson H; Dias A; Mikropoulos C; Izatt L; Side L; Walker L; Donaldson A; Cook JA; Barwell J; Wiles V; Limb L; Eccles DM; Leach MO; Shanley S; Gilbert FJ; Gallagher D; Rajashanker B; Whitehouse RW; Koh DM; Sohaib SA; Evans DG; Eeles RA; Walker LG
    J Med Genet; 2020 Apr; 57(4):226-236. PubMed ID: 31719169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort.
    Mai PL; Khincha PP; Loud JT; DeCastro RM; Bremer RC; Peters JA; Liu CY; Bluemke DA; Malayeri AA; Savage SA
    JAMA Oncol; 2017 Dec; 3(12):1640-1645. PubMed ID: 28772286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1.
    Kumamoto T; Yamazaki F; Nakano Y; Tamura C; Tashiro S; Hattori H; Nakagawara A; Tsunematsu Y
    Int J Clin Oncol; 2021 Dec; 26(12):2161-2178. PubMed ID: 34633580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic accuracy of imaging approaches for early tumor detection in children with Li-Fraumeni syndrome.
    Tewattanarat N; Junhasavasdikul T; Panwar S; Joshi SD; Abadeh A; Greer MLC; Goldenberg A; Zheng G; Villani A; Malkin D; Doria AS
    Pediatr Radiol; 2022 Jun; 52(7):1283-1295. PubMed ID: 35391548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric cancer and Li-Fraumeni/Li-Fraumeni-like syndromes: a review for the pediatrician.
    Giacomazzi CR; Giacomazzi J; Netto CB; Santos-Silva P; Selistre SG; Maia AL; Oliveira VZ; Camey SA; Goldim JR; Ashton-Prolla P
    Rev Assoc Med Bras (1992); 2015; 61(3):282-9. PubMed ID: 26248253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline surveillance in Li Fraumeni syndrome using whole-body MRI: a systematic review and updated meta-analysis.
    Dacoregio MI; Abrahão Reis PC; Gonçalves Celso DS; Romero LE; Altmayer S; Vilbert M; Moraes FY; Gomy I
    Eur Radiol; 2024 Jul; ():. PubMed ID: 39075300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-body magnetic resonance imaging as surveillance for subsequent malignancies in preadolescent, adolescent, and young adult survivors of germline retinoblastoma: An update.
    Friedman DN; Hsu M; Moskowitz CS; Francis JH; Lis E; Fleischut MH; Oeffinger KC; Walsh M; Tonorezos ES; Sklar CA; Abramson DH; Dunkel IJ
    Pediatr Blood Cancer; 2020 Jul; 67(7):e28389. PubMed ID: 32386119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Applications and Controversies of Whole-Body MRI:
    Ahlawat S; Debs P; Amini B; Lecouvet FE; Omoumi P; Wessell DE
    AJR Am J Roentgenol; 2023 Apr; 220(4):463-475. PubMed ID: 36169545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of interim blood tests for cancer screening in Li-Fraumeni syndrome.
    Oba L; Best AF; Mai PL; Achatz MI; Albert PS; Savage SA; Khincha PP
    Fam Cancer; 2022 Jul; 21(3):333-336. PubMed ID: 34076823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-body MRI surveillance in TP53 carriers is perceived as beneficial with no increase in cancer worry regardless of previous cancer: Data from the Swedish TP53 Study.
    Omran M; Johansson H; Lundgren C; Silander G; Stenmark-Askmalm M; Loman N; Baan A; Adra J; Kuchinskaya E; Blomqvist L; Tham E; Bajalica-Lagercrantz S; Brandberg Y;
    Cancer; 2023 Mar; 129(6):946-955. PubMed ID: 36601958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Li-Fraumeni syndrome].
    Keymling M; Schlemmer HP; Kratz C; Pfeil A; Bickelhaupt S; Alsady TM; Renz DM
    Radiologie (Heidelb); 2022 Dec; 62(12):1026-1032. PubMed ID: 36166074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Embodied risk for families with Li-Fraumeni syndrome: Like electricity through my body.
    Werner-Lin A; Forbes Shepherd R; Young JL; Wilsnack C; Merrill SL; Greene MH; Khincha PP
    Soc Sci Med; 2022 May; 301():114905. PubMed ID: 35367908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls.
    Saya S; Killick E; Thomas S; Taylor N; Bancroft EK; Rothwell J; Benafif S; Dias A; Mikropoulos C; Pope J; Chamberlain A; Gunapala R; ; Izatt L; Side L; Walker L; Tomkins S; Cook J; Barwell J; Wiles V; Limb L; Eccles D; Leach MO; Shanley S; Gilbert FJ; Hanson H; Gallagher D; Rajashanker B; Whitehouse RW; Koh DM; Sohaib SA; Evans DG; Eeles RA
    Fam Cancer; 2017 Jul; 16(3):433-440. PubMed ID: 28091804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.